The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $15.87 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Bob Duggan & Maky Zanganeh, Summit Therapeutics co-CEOs, join 'Fast Money' to talk its lung cancer drug and continuing ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

The future of health care is being rewritten right now. Artificial intelligence (AI), digital therapeutics and game-changing ...